<DOC>
	<DOCNO>NCT01910844</DOCNO>
	<brief_summary>Study assess efficacy Cisplatine- Métronomic cyclophosphamide treatment Patients Metastatic Triple Negative breast Cancer Secondary Resistant Anthracyclines Taxanes .</brief_summary>
	<brief_title>Phase II Pilot Study Assessing Efficacy Cisplatin - Métronomic Cyclophosphamide Treatment Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant Anthracyclines Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Performance status &lt; 2 , Patient metastatic breast cancer stade IV triple negative histologically confirm Measurable disease radiologically evaluable ( RECIST 1.1 ) , Negative Hormonal Receptors ( Estrogens and/or Progesterone ) , HER2 negative ( Score 0 1 Immunochemistry ( IHC ) , negative FISH score IHC 2 ) , Patient expose anthracyclines and/or taxanes neoadjuvant adjuvant setting , Patient progression anthracyclines and/or taxanes treatment deliver accord resistance define : In last 12 month last dose taxanes anthracyclines adjuvant neoadjuvant setting , During first metastatic chemtotherapy line taxanes anthracyclines deliver accord : either secondary resistance initial response chemotherapy relapse observe either treatment 4 month end chemotherapy . either sensitivity treatment define relapse 4 month first chemotherapy metastatic line , either intolerance anthracyclines ( doxorubicin 240400 mg/m² ou equivalent doxorubicin ( epirubicin ) 300550mg/m² ) Patient non previously treat platinum salt , Hematological Functions : Neutrophiles ≥ 1,5.109/L , Platelets ≥ 100.109/L , Leucocytes &gt; 3 000/mm3 , Hb &gt; 9g/dL , Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal value ( UNV ) , ASAT ≤ 2 ,5 time UNV , ALAT ≤ 2,5 time UNV , Alkaline Phosphatase ≤ 2,5 time UNV ( &lt; 5 time UNV case hepatic metastasis ) , Renal Functions : Serum Creatinine ≤ 1,5 time UNV ( value &gt; 1,5 time UNV , Clearance ≥ 60 mL/min ) Clearance ≥ 40 mL/min case RMI , Patient sign consent study form , Patient affiliate social security regimen ( law 9 August 2004 ) . Male Patients , Unknown hormonal Receptors Positive HER2 ( Score 3 IHC positive FISH ) Pregnant breastfeed patient , age pregnancy predict pregnant 6 month end treatment , Patient use contraceptive treatment treatment 6 month end treatment , Patient ward , Patient suffer non compatible disease enrollment study , Cardiac , renal , medullar , respiratory hepatic insufficiency , clinically significant cardiovascular disease ( include myocardiac infarct , unstable angina , symptomatic congestive heart failure , uncontrolled cardiac arrhythmia ) &lt; 1 year study enrollment randomisation , Patient pulmonary lymphangitis symptomatic pleural effusion ( grade≥2 ) , meningeal know carcinoma symptom cerebromeningeal invasion , brain metastasis unless treatment stability least 4 week ( steroid anticonvulsive ) . Uncontrolled diabetes , Psychiatric neurological significant abnormality , Peripheric Neuropathy &gt; grade 2 , Antecedent hypersensibility one study treatment one use excipients , Urinary tract infection acute hemorrhagic cystitis progress Concomitant treatment medicine contain phenytoin medication receive context trial , participation another therapeutic clinical trial within &lt; 30 day prior treatment chemotherapy . Geographically unstable patient next 6 month remain distance treatment center make difficult follow study , Known history abuse narcotic drug alcohol History surgery within 28 day start treatment , Patient unwilling unable comply requirement study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>late-relapse</keyword>
</DOC>